Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

23,622 signal articles · 323 in last 24h · 112,499 total before filter · latest 22m ago
323last 24h
2137last 7d
380● bullish (7d)
184● bearish (7d)
204publishers
AllMacro301Earnings1207M&A92Regulatory23Product13Analyst20
✕ clear all filtersticker: ^GSPCsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
How Friday’s Jobs Report Could Push Treasury Yields Lower
Barrons.com6d agoneutral
How Friday’s Jobs Report Could Push Treasury Yields Lower

Treasury yields have given back some of their recent summer surge. What happens next will likely depend on the chances of a longer term peace agreement between the U.S. and Iran and the Federal Reserve’s reaction to Friday’s jobs report. Longer-dated 30-year paper, meanwhile, was marked at 5.176%, down around 8 basis points from last week’s peak of 5.25%, the highest since 2007.

Charles River Laboratories International Q2 Earnings Call Highlights
MarketBeat7d agoneutral
Charles River Laboratories International Q2 Earnings Call Highlights

Charles River Laboratories International (NYSE:CRL) reported second-quarter results that exceeded its prior outlook, citing improved demand in its Discovery and Safety Assessment, or DSA, business and stronger-than-expected manufacturing performance. The company raised its full-year revenue, earning

Michael Burry sends loud signal to stock market investors
TheStreet7d agoneutral
Michael Burry sends loud signal to stock market investors

Wall Street hit a milestone on Aug. 4 that would normally silence the skeptics. The S&P 500 closed at a record high for the first time since June, and the Nasdaq Composite followed. Both were powered by stronger-than-expected corporate earnings and falling oil prices tied to hopes the Strait of ...

Axon Stock Resurgence Faces Q2 Earnings Test
Investor's Business Daily7d agoneutral
Axon Stock Resurgence Faces Q2 Earnings Test

Axon Enterprise, the S&P 500 maker of Tasers, body cameras and software for law enforcement, continued its resurgence this week ahead of its Q2 report after today's close. This week's jolt higher may mean it could take a stunning report to maintain upward momentum for Axon stock. Earnings growth is up against what looks like a low bar, but that's only because EPS vaulted 77% in the year-ago quarter.

Is Chipotle a Buy, Sell, or Hold After 2 Years of Volatility?
24/7 Wall St.7d agoneutral
Is Chipotle a Buy, Sell, or Hold After 2 Years of Volatility?

Chipotle's share price has swung wildly for two years, and now management is buying back stock aggressively near current levels while Wall Street eyes a 27% upside. The real question is whether the operational recovery has enough traction to survive margin pressure, a fragile consumer, and fresh food safety concerns.

SpaceX’s $1T Goal and 3 More Shockers From Musk on the Earnings Call
Barrons.com7d agoneutral
SpaceX’s $1T Goal and 3 More Shockers From Musk on the Earnings Call

SpaceX and Tesla CEO Elon Musk is famous for his sky-high ambitions, including reaching Mars one day. After SpaceX’s earnings report Tuesday, Musk laid out four more brazen goals for the rocket and artificial-intelligence company, including reaching $1 trillion in revenue in less than five years. SpaceX stock tumbled 8% to $115.29 on Wednesday, while the S&P 500 edged up 0.1%.

Veteran analyst rethinks Palantir stock after earnings
TheStreet7d agoneutral
Veteran analyst rethinks Palantir stock after earnings

Palantir stock has struggled for months, but the company may have just given investors some hope again. Shares of Palantir surged 29.45% on Aug. 4, the trading day after Palantir reported second-quarter results that topped Wall Street's expectations. The company posted adjusted earnings of 41 cents ...

Lilly Stock Jumps on Earnings Beat as Mounjaro Revenue Nearly Doubles
Barrons.com7d agoneutral
Lilly Stock Jumps on Earnings Beat as Mounjaro Revenue Nearly Doubles

Eli Lilly posted a blockbuster second quarter fueled by continued demand for its portfolio of GLP-1 medications. The world’s biggest drugmaker by market value reported adjusted earnings of $8.38 a share in the period, better than the $6.01 consensus estimate among analysts polled by FactSet. Revenue surged 48% to nearly $23 billion—Wall Street was looking for $20.7 billion.

Morning Bid: Outer SpaceX
Reuters8d agoneutral
Morning Bid: Outer SpaceX

August 5 (Reuters) - What matters in U. and global markets today , Editor-at-Large, Finance and Markets For all the doubts and handwringing, the S&P; 500 and Dow Jones are back at record highs after surging on Tuesday amid falling oil prices and the bumper earnings season.

Middle East optimism lifts sentiment as SpaceX and AMD earnings dominate attention: Dow Jones, S&P, Nasdaq, Wall Street Futures
InvestorsHub8d agoneutral
Middle East optimism lifts sentiment as SpaceX and AMD earnings dominate attention: Dow Jones, S&P, Nasdaq, Wall Street Futures

US stock futures edged higher on Wednesday as investors reacted to renewed hopes of easing tensions in the Middle East, while corporate earnings from SpaceX (NASDAQ:SPCX), Advanced Micro Devices (NASDAQ:AMD) and Novo Nordisk (NYSE:NVO) drove significant pre-market trading. Although geopolitical developments supported overall market sentiment, investors also assessed company-specific news, particularly Elon Musk’s latest comments, which weighed on both SpaceX and AMD shares.